Exeliom

About:

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.

Website: https://www.exeliombio.com

Top Investors: Bpifrance, European Innovation Council, UI Investissement, Capital Grand Est, Biocodex

Description:

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies. Exeliom develops a new class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system. The company was founded in 2016 and is headquartered in Dijon, France.